Abstract:Abstract Case presentation During the last year, a 66-year-old man was repetitively hospitalized for anasarcatic heart failure in an infiltrative heart disease with an impaired left ventricular function. In March 2022 the patient first presented to our emergency department with clinical signs of decompensated heart failure. An accurate diagnosis was made during the inpatient care. The electrocardiogram documented sinus bradycardia, degree I atrioventricular block, and right bundle branch block. Echocardiography showed a slight reduction in biventricular function, concentric hypertrophy and a significant reduction in longitudinal systolic function (GLS -11.8%) with an apical-sparing pattern. At the same time, the presence of mild to moderate circumferential pericardial effusion was documented. According to the clinical suspicion, a cardiac MRI was performed, revealing consistent amyloid infiltrative disease. A 99-mTc-HDP myocardial scintigraphy confirmed pathological accumulation of trans-thyretine with a Perugini Score 2. Serum and urinary immunofixation were negative. A genetic test was subsequently performed whereby a heterozygous Ile68Leu (p.Ile88Leu) pathogenic mutation in the TTR gene was documented. Follow-up neurologic evaluation ruled out the indication to start Patisiran therapy due to the absence of significant neurologic involvement. In the meantime, the patient was put on Torasemide therapy with moderate clinical benefit. Few months ago, shortly after the diagnosis, the patient was hospitalized again for anasarcatic heart failure complicated by a severe ascites, underwent a paracentesis. During this hospitalization, therapy with Tafamidis was started. The patient is currently in good cardiovascular clinical compensation. Discussion This clinical case offers the chance to investigate the characteristics and phenotype of cardiac amyloidosis caused by the Ile68Leu mutation. The typical Ile68Leu ATTRm patient is caucasian, tipically a 70 years’man (slightly younger than ATTRwt fenotipe), seeks medical attention with heart failure symptoms, and receives the correct diagnosis of cardiac amyloidosis almost 1 year after the onset of these symptoms. Usually, the mutation leads to predominantly cardiac manifestations, instead of a combined form (cardiac and/or neurological manifestations). The Ile68Leu TTR mutation is a cause of cardiac amyloidosis that leads to a phenotype similar to ATTRwt. The electrocardiogram and echocardiogram features described in the clinical case are typical and often indistinguishable from that of ATTRwt. The age at diagnosis and advanced heart failure symptoms at presentation were the only factors independently associated with mortality. The subject patient is younger than the average affected ones and suffers from an aggressive form of the disease. The take home message could be that we should definitely learn and remember the importance of etiologic screening in infiltrative diseases, especially in young people, now that there are effective therapies capable to reduce mortality and improve quality of life.

G Protein Regulation of Inwardly Rectifying K(+) Channels.

Clinical Features of Familial Amyloid Polyneuropathy Carrying Transthyretin Mutations in Four Chinese Kindreds

Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy

A Case of Familial Amyloid Polyneuropathy with a Transthyretin Glu54Lys Mutation

Ocular Manifestations in a Chinese Pedigree of Familial Amyloidotic Polyneuropathy Carrying the Transthyretin Mutation c.401A>G (p.Tyr134Cys)

Higher education in gerontology: A comparison of master’s programs in Japan, Taiwan, and Turkey

A Study of Familial Amyloid Polyneuropathy Induced by the TTR Val30Leu Mutation in China

635 AMYLOIDOSIS AND THE ILE68LEU MUTATION OF THE TTR GENE: A RARE DISEASE YOU CAN TREAT.

Clinical pathology and molecular genetics on familial amyloidotic polyneuropathy]

Diagnosis of sporadic transthyretin Val30Met familial amyloid polyneuropathy: a practical analysis

Characterization of Transthyretin Mutation G47V Associated with Hereditary Cardiac Amyloidosis

First case of symptomatic transthyretin cardiac amyloidosis with rare Tyr78Phe variant, normal left ventricular wall thickness, and no cardiac uptake on scintigraphy

Cardiovascular autonomic failure in hereditary transthyretin amyloidosis and TTR carriers is an early and progressive disease marker

[On the mechanism of the anti-succinylcholine action of imipramine. (Demonstration, on the frog abdominal rectus, of an imipramine action inhibiting depolarizing drugs)].

Clinical and biochemical characterization of asymptomatic carriers and symptomatic patients with hereditary transthyretin amyloidosis caused by TTR V30L mutation

Clinical and Biochemical Characterization of Hereditary Transthyretin Amyloidosis Caused by E61K Mutation

Hereditary Transthyretin Amyloidosis in Eight Chinese Families.

Somatic mosaicism with reversion to normality of a mutated transthyretin allele related to a familial amyloidotic polyneuropathy

Transthyretin (Pro24Ser) variant amyloidosis: A case report of the first patient in Greece

Case Report and Literature Review: A De Novo Pathogenic Missense Variant in ACTN4 Gene Caused Rapid Progression to End-Stage Renal Disease

Improvized pneumatic dilator for achalasia cardia.